Keren Osman, MD
- ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology
MD, Mount Sinai School of Medicine
Residency, Internal Medicine, Mount Sinai Hospital
Fellowship, Medical Oncology, Memorial Sloan-Kettering Cancer Center
- BMT CTN 1302: A Multicenter Phase II, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma
Multiple Myeloma is a cancer of the blood that begins in the bone marrow, a cancer that is currently incurable and even interventions that work may stop working after some time. This recurrence of cancer is known as relapse. Allogeneic Stem Cell Transplantation (AS...
- Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients with Relapsed AL Amyloidosis
The purpose of this study is to see if the combination of bendamustine and dexamethasone will help people with amyloidosis that has returned after standard treatment.
Bendamustine is currently approved by the Food and Drug Administration (FDA) for treatment of chroni...
- Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702
The purpose of this study is to learn how well maintenance treatment (chemotherapy) works to control your disease long-term (more than 3 years after transplant). Multiple Myeloma (MM) is a cancer of the blood. Because there's no cure for MM, maintenance treatment i...